Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A

Hepatology

Volumn 49, Issue 1, 2009, Pages 106-115

  Rodríguez Calvo, Ricardo ^a   Barroso, Emma ^a   Serrano, Lucía ^a   Coll, Teresa ^a   Sánchez, Rosa M ^a   Merlos, Manuel ^a   Palomer, Xavier ^a   Laguna, Juan C ^a   Vázquez Carrera, Manuel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CARBOHYDRATE BINDING PROTEIN; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FATTY ACID; FRUCTOSE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; WBSCR14 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REGULATION; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FOOD INTAKE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; ANIMAL; BLOOD; CARBOHYDRATE DIET; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIETARY CARBOHYDRATES; ENZYME ACTIVATION; FATTY ACIDS, NONESTERIFIED; FRUCTOSE; GLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE; HEPTANOIC ACIDS; HUMANS; MALE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 58949094416     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22570     Document Type: Article

References (38)

1. Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004;79:774-779.
2. Hallfrisch J. Metabolic effects of dietary fructose. FASEB J 1990;4:2652-2660.
3. Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, Shillinglaw W, et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A 2001;98: 9116-9121.
4. Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/ dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci U S A 2001;98:13710-13715.
5. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006;4:107-110.
6. Kelley GL, Azhar S. Reversal of high dietary fructose-induced PPARalpha suppression by oral administration of lipoxygenase/cyclooxygenase inhibitors. Nutr Metab (Lond) 2005;2:18.
7. Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: Evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 2002;51:409-418.
8. Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005;179:43-49.
9. Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, et al. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. HEPATOLOGY 2007;45:778-788.
10. Roglans N, Sanguino E, Peris C, Alegret M, Vazquez M, Adzet T, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002;302:232-239.
11. Ericsson J, Jackson SM, Kim JB, Spiegelman BM, Edwards PA. Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J Biol Chem 1997;272:7298-7305.
12. Jerkins AA, Liu WR, Lee S, Sul HS. Characterization of the murine mitochondrial glycerol-3-phosphate acyltransferase promoter. J Biol Chem 1995;270:1416-1421.
13. van der Leij FR, Kram AM, Bartelds B, Roelofsen H, Smid GB, Takens J, et al. Cytological evidence that the C-terminus of carnitine palmitoyltransferase I is on the cytosolic face of the mitochondrial outer membrane. Biochem J 1999;341:777-784.
14. Gonzalez-Baro MR, Granger DA, Coleman RA. Mitochondrial glycerol phosphate acyltransferase contains two transmembrane domains with the active site in the N-terminal domain facing the cytosol. J Biol Chem 2001;276:43182-43188.
15. Linden D, William-Olsson L, Rhedin M, Asztely AK, Clapham JC, Schreyer S. Overexpression of mitochondrial GPAT in rat hepatocytes leads to decreased fatty acid oxidation and increased glycerolipid biosynthesis. J Lipid Res 2004;45:1279-1288.
16. Lewin TM, Wang S, Nagle CA, Van Horn CG, Coleman RA. Mitochondrial glycerol-3-phosphate acyltransferase-1 directs the metabolic fate of exogenous fatty acids in hepatocytes. Am J Physiol Endocrinol Metab 2005;288:E835-E844.
17. Hammond LE, Neschen S, Romanelli AJ, Cline GW, Ilkayeva OR, Shulman GI, et al. Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs. J Biol Chem 2005;280:25629-25636.
18. Hammond LE, Gallagher PA, Wang S, Hiller S, Kluckman KD, Posey-Marcos EL, et al. Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. Mol Cell Biol 2002;22:8204-8214.
19. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128-133.
20. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 1998;18:783-793.
21. Wilcox LJ, Barrett PH, Huff MW. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res 1999;40:1078-1089.
22. Coll T, Jove M, Rodriguez-Calvo R, Eyre E, Palomer X, Sanchez RM, et al. Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha in skeletal muscle cells involves MEK1/ 2 and nuclear factor-kappaB activation. Diabetes 2006;55:2779-2787.
23. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: Pitfalls and potential. Biotechniques 1999;26:112-115.
24. Dircks LK, Sul HS. Mammalian mitochondrial glycerol-3-phosphate acyltransferase. Biochim Biophys Acta 1997;1348:17-26.
25. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004;287:H560-H566.
26. Brady PS, Park EA, Liu JS, Hanson RW, Brady LJ. Isolation and characterization of the promoter for the gene coding for the 68 kDa carnitine palmitoyltransferase from the rat. Biochem J 1992;286(Pt 3):779-783.
27. Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, Takahashi A, et al. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 2007;282:11687-11695.
28. Shoji S, Titani K, Demaille JG, Fischer EH. Sequence of two phosphorylated sites in the catalytic subunit of bovine cardiac muscle adenosine 3′5′-monophosphate-dependent protein kinase. J Biol Chem 1979;254: 6211-6214.
29. Muoio DM, Seefeld K, Witters LA, Coleman RA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: Evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 1999;338(Pt 3):783-791.
30. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997;8:146-153.
31. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A 2004;101:7281-7286.
32. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-2838.
33. Denechaud PD, Bossard P, Lobaccaro JM, Millatt L, Staels B, Girard J, et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest 2008;118:956-964.
34. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006;55:2159-2170.
35. Linden D, William-Olsson L, Ahnmark A, Ekroos K, Hallberg C, Sjogren HP, et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J 2006;20:434-443.
36. Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderman NB, et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 2002;277:32571-32577.
37. Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, Takahashi A, et al. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 2007;282:11687-11695.
38. Lu M, Shyy JY. Sterol regulatory element-binding protein 1 is negatively modulated by PKA phosphorylation. Am J Physiol Cell Physiol 2006;290: C1477-C1486.